Study: LSD Microdosing Boosts Women's Sustained Attention

Summary:

A randomized, double-blind pilot study from Maastricht University shows that repeated low doses of LSD can substantially improve sustained attention and reduce attention lapses in women, while producing no measurable cognitive benefit in men under the same conditions. These preliminary results challenge broad claims about the universal benefits of psychedelic microdosing and point toward the need for personalized approaches that consider biological sex and individual variability.

Key Facts:

Sex-specific attention gains: Women who received microdoses of LSD responded about 8% faster (mean reaction time 308 ms versus 335 ms) and experienced roughly half as many sustained-attention lapses (2.3 vs. 4.7) compared with women on placebo.
No comparable effect in men: Male participants given identical low doses of LSD did not show the same improvements in sustained attention.
Task-specific effects: The observed benefit was selective to sustained vigilance; tasks measuring information processing speed and working memory did not show clear improvements attributable to microdosing.

Source: European College of Neuropsychopharmacology (ECNP) / Maastricht University

Psychedelic microdosing — taking sub-perceptual amounts of substances such as lysergic acid diethylamide (LSD) — has become popular as an informal strategy to boost productivity, concentration, and mood. Controlled clinical evidence, however, has been mixed, leaving open whether reported benefits are pharmacological, placebo-driven, or dependent on who is using them. This pilot study offers initial evidence that biological sex may be an important factor influencing whether microdosing yields measurable cognitive effects.

Presented as preliminary data at the ECNP annual congress, the trial evaluated how low, sub-hallucinogenic doses of LSD affected multiple cognitive domains across repeated administrations. The investigators focused on sustained attention because lapses in vigilance are common in daily tasks and have clear real-world relevance for safety and productivity.

Study design and participants

Forty-eight healthy adults (24 women, 24 men; mean age 36.9 years) participated in a double-blind experiment over two weeks. Participants were randomized to receive either placebo or four doses of 15 micrograms of LSD each. At this dosage, participants are unlikely to experience full psychedelic effects, which typically occur at substantially higher doses. Cognitive testing occurred at baseline, after the first dose, after the fourth dose, and during a follow-up assessment, with neither participants nor study staff aware of treatment allocation during data collection.

Researchers assessed three cognitive dimensions: working memory, information processing speed, and sustained attention. Sustained attention was measured with a continuous vigilance task that requires rapid, accurate responses to visual stimuli — a standard approach for detecting subtle changes in attentional control.

Findings: a clear sex difference in sustained attention

At baseline, women in the placebo group tended to show slower reaction times and more frequent attention lapses than men. After microdosing, women in the LSD group exhibited a pronounced improvement in sustained vigilance:

Faster responses: Mean reaction time for women improved from 335 milliseconds on placebo to 308 milliseconds under LSD — about an 8% reduction.
Fewer lapses: Average sustained-attention lapses among women dropped from 4.7 under placebo to 2.3 following LSD administration.

These benefits emerged after the first dose, persisted after repeated dosing, and remained detectable at follow-up. Men who received identical microdoses did not show similar improvements compared with male placebo participants. Tasks assessing information processing and working memory produced no decisive differences between drug and placebo groups, suggesting the effect is domain-specific rather than a general cognitive boost.

Interpreting the results: caution and next steps

Lead researcher Iva Totomanova of Maastricht University emphasized that these findings do not imply LSD is a universal cognitive enhancer for women or that women are inherently more responsive to psychedelics. “The key finding was that LSD improves how women can sustain attention in certain tasks,” Totomanova said. “This does not show that low-dose LSD generally improves cognition, nor that women are generally more responsive to LSD than men. Instead, the results point to a more cautious message: effects may depend on the person, the cognitive task being measured, and the circumstances of use.”

Because the analysis was carried out as a post-hoc re-examination of clinical trial data, the authors call for prospectively designed studies that explicitly account for physiological and hormonal variables such as circulating ovarian hormones, menstrual cycle phase, and the use of hormonal contraceptives. Larger, preregistered trials can better determine whether the sex-specific effect on sustained attention replicates and identify biological or behavioral predictors of response.

Toward precision approaches in psychedelic research

Independent experts note that rigorous trials are essential to move beyond anecdote and media hype. Dr. Mikkel Højlund of the University of Southern Denmark, not involved in the study, stressed that while the double-blind, placebo-controlled design is strong, the sample size is small and the results warrant replication on a larger scale. The findings nonetheless highlight how individual differences — including biological sex — may shape the cognitive and sensory effects of psychedelics.

As research into psychedelic therapeutics progresses toward clinical validation and potential regulatory use, these data underscore the limitations of one-size-fits-all assumptions. Personalized, mechanism-aware approaches may be necessary to understand when and for whom low-dose psychedelics can produce meaningful cognitive changes.